Send to

Choose Destination
Horm Res Paediatr. 2010;74(4):259-66. doi: 10.1159/000289570. Epub 2010 Apr 30.

Height at start, first-year growth response and cause of shortness at birth are major determinants of adult height outcomes of short children born small for gestational age and Silver-Russell syndrome treated with growth hormone: analysis of data from KIGS.

Author information

Paediatric Endocrinology Section, University Children's Hospital, Tübingen, Germany.



There is limited information about adult height (AH) outcomes and the factors influencing outcomes of growth hormone (GH) therapy in short children born small for gestational age (SGA).


AH (SDS) and Δheight (SDS) from GH start to AH were analyzed in 161 SGA children who had reached AH (55 with Silver-Russell syndrome, SRS).


SGA patients treated to AH were started on GH (median) 0.25 mg/kg/week at an age of 7.8 years with a height of -3.8 SDS. AH after 7.7 years was -2.2 SDS and -1.1 SDS below mid-parental height (MPH). AH (SDS) was explained by: height (SDS) at GH start (+), Δheight (SDS) 1st year on GH (+), years on GH (+), maternal height (SDS) (+), length (SDS) at birth (+), and the diagnosis of SRS (-) (explained variability 70%; error 0.6 SD). Gain in height (SDS) was explained by: Δheight (SDS) 1st year on GH (+), years on GH (+), height - MPH (SDS) at GH start (-) (explained variability 60%; error 0.7 SD).


Algorithms for AH outcomes provides useful information about the potential of long-term growth on GH in short children born SGA.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center